uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of uniQure (NASDAQ:QURE) from a sell rating to a hold rating in a report issued on Saturday.

A number of other research analysts have also weighed in on QURE. Leerink Partners raised their price target on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Wells Fargo & Company boosted their price objective on uniQure from $60.00 to $75.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Royal Bank Of Canada increased their target price on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Mizuho raised their target price on uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Finally, HC Wainwright lifted their price target on uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and an average price target of $65.00.

uniQure Stock Performance

NASDAQ:QURE opened at $47.97 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01. The company has a fifty day moving average of $41.68 and a two-hundred day moving average of $28.04. The stock has a market capitalization of $3.33 billion, a PE ratio of -11.96 and a beta of 0.93. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The company had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same quarter last year, the business earned ($0.69) EPS. As a group, research analysts forecast that uniQure will post -3.74 earnings per share for the current fiscal year.

Insider Activity

In other uniQure news, Director Madhavan Balachandran sold 11,685 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the transaction, the director directly owned 43,254 shares of the company’s stock, valued at $1,949,025.24. This trade represents a 21.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 164,429 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total value of $7,287,493.28. Following the transaction, the chief executive officer owned 558,810 shares in the company, valued at approximately $24,766,459.20. This represents a 22.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 388,229 shares of company stock valued at $16,817,099 in the last ninety days. 4.65% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On uniQure

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Torren Management LLC purchased a new position in uniQure during the fourth quarter worth approximately $28,000. IFP Advisors Inc purchased a new stake in uniQure in the 4th quarter valued at $48,000. Smartleaf Asset Management LLC purchased a new stake in uniQure in the 4th quarter valued at $48,000. CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure in the 3rd quarter worth $50,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of uniQure by 42.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 906 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.